𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer

✍ Scribed by Hansjochen Wilke; Peter Preusser; Michael Stahl; Andreas Harstrick; Hans-Joachim Meyer; Wolf Achterrath; Hans-Joachim Schmoll; Siegfried Seeber

Publisher
Springer
Year
1991
Tongue
English
Weight
183 KB
Volume
29
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

High dose folinic acid/etoposide/5-fluor
High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer β€” a phase II study in elderly patients or patients with cardiac risk
✍ H. Wilke; P. Preusser; U. Fink; W. Achterrath; L. Lenaz; M. Stahl; C. Schober; H πŸ“‚ Article πŸ“… 1990 πŸ› Springer US 🌐 English βš– 389 KB

Thirty-four consecutive patients with measurable advanced gastric cancer were treated in a disease oriented Phase II study with high-dose folinic acid (HDFA) 300 mg/m2 10 min. inf., followed immediately by etoposide 120 mg/m2 50 min. inf., followed immediately by 5-fluorouracil (5-FU) 500 mg/m2 10 m

Randomized phase III Study of 5-fluorour
Randomized phase III Study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer
✍ Dennie V. Jones; Roger J. Winn; Barry W. Brown; Lawrence B. Levy; Reginald P. Pu πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 501 KB

Background. Metastatic colorectal cancer is generally incurable. The most active regimen available, 5-fluorouracil(5-FU) and folinic acid (Leucovorin), produces response rates of approximately 25% to 30%. Methyl-lomustine is a nitrosourea with modest activity against colorectal cancer. A randomized